AMR Action Fund Announces Investment in BioVersys AG

  06 January 2023

The AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antimicrobials, announced that it has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund’s first investment in Europe and is an important step toward building an international portfolio of companies that are developing urgently needed antimicrobials.

Drug-resistant bacterial infections were associated with nearly 5 million deaths in 2019 and directly killed 1.27 million people, more than HIV or malaria. BioVersys’ lead candidate, BV100, is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB). Recent research published in The Lancet showed that CRAB infections could kill as many as 100,000 people a year. The World Health Organization and the U.S. Centers for Disease Control and Prevention have identified CRAB as one of the highest-priority pathogens for which new treatments are needed.

Further reading: AMR Action Fund
Author(s): AMR Action Fund
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed